On-line Table: Predictors of ischemic complications

|  | No Complications         | Complications            | P Value     |  |
|--|--------------------------|--------------------------|-------------|--|
| Parameter                                  | (n = 100)                | (n = 29)                 | Univariable | Multivariable                            |
| Sex  | (( (00 50/)              | 1/ /10 59/)              | 30          |  |
| Female<br>Male                             | 66 (80.5%)<br>34 (72.3%) | 16 (19.5%)<br>13 (27.7%) | .29         | _  |
| Median age (range) (yr)                    | 58 (29–78)               | 54 (29–82)               | .86         | _  |
| Smoking <sup>a</sup>                       | 30 (27 70)               | 54 (27 02)               | .00         |  |
| Yes  | 36 (90%)                 | 4 (10%)                  | .02         | OR, 0.2; 95% CI, 0.05 $-0.7$ ; $P = .07$ |
| No   | 57 (71.3%)               | 23 (28.8%)               |             |  |
| resenting symptoms                         | , ,                      | , ,                      |             |  |
| Asymptomatic                               | 23 (82.1%)               | 5 (17.9%)                | .2          | _  |
| Headache/dizziness                         | 26 (8.7%)                | 4 (13.3%)                |             |  |
| Neurologic deficit                         | 51 (71.8%)               | 20 (28.2%)               |             |  |
| ubarachnoid hemorrhage                     |                          | 6 3                      |             |  |
| No   | 69 (75.8%)               | 22 (24.2%)               | .17         | _  |
| Acute (<24 hr)                             | 6 (100%)                 | 0%                       |             |  |
| Immediate (<2 wk)                          | 13 (92.9%)               | 1 (7.1%)                 |             |  |
| Remote (>2 wk)                             | 12 (66.7%)               | 6 (33.3%)                |             |  |
| retreatment mRS                            | 01 (00 20/)              | 20 /10 00/\              | 17          |  |
| 0–2<br>3–5                                 | 81 (80.2%)<br>19 (67.9%) | 20 (19.8%)<br>9 (32.1%)  | .17         | _  |
| neurysm location                           | 17 (0/.7/0)              | 7 (32.1/0)               |             |  |
| VA   | 38 (84.4%)               | 7 (15.6%)                | .48         | _  |
| Vertebrobasilar artery                     | 13 (72.2%)               | 5 (27.8%)                | 10          | _  |
| PICA                                       | 8 (88.9%)                | 1 (11.1%)                |             |  |
| Basilar artery                             | 32 (69.6%)               | 14 (30.4%)               |             |  |
| SCA  | 2 (66.7%)                | 1 (33.3%)                |             |  |
| PCA  | 7 (87.5%)                | 1 (12.5%)                |             |  |
| neurysm shape                              | ,                        | ,                        |             |  |
| Saccular                                   | 36 (76.6%)               | 11 (23.4%)               | .7          | _  |
| Fusiform                                   | 38 (74.5%)               | 13 (25.5%)               |             |  |
| Dissecting                                 | 24 (82.8%)               | 5 (17.2%)                |             |  |
| neurysm measurements                       |                          |                          |             |  |
| Maximal diameter                           |                          |                          |             |  |
| <7 mm                                      | 18 (81.8%)               | 4 (18.2%)                | .11         | _  |
| 7–12 mm                                    | 38 (88.4%)               | 5 (11.6%)                |             |  |
| 13–24 mm                                   | 27 (69.2%)               | 12 (30.8%)               |             |  |
| >24 mm                                     | 17 (68%)                 | 8 (32%)                  |             |  |
| Daughter sac                               | 21 (00 00/)              | F (10 20/)               | "           |  |
| Yes<br>No                                  | 21 (80.8%)               | 5 (19.2%)                | .66         | <del>-</del>                             |
|  | 79 (76.7%)               | 24 (23.3%)               |             |  |
| ntra-aneurysmal thrombus<br>Yes            | 25 (64.1%)               | 14 (35.9%)               | .02         | OR, 2.7; 95% CI, 0.9–7.8; P = .06        |
| No   | 75 (83.3%)               | 15 (16.7%)               | .02         | OR, 2.7, 93% CI, 0.9-7.8, 7 = :00        |
| rior treatment                             | 75 (03.378)              | 13 (10.778)              |             |  |
| No   | 84 (75%)                 | 28 (25%)                 | .37         | _  |
| Endovascular                               | 13 (92.9%)               | 1 (7.1%)                 | .57         |  |
| Surgery                                    | 2 (100%)                 | 0%                       |             |  |
| Both                                       | 1 (100%)                 | 0%                       |             |  |
| latelet function testing                   | ,                        |                          |             |  |
| Yes  | 64 (83.1%)               | 13 (16.9%)               | .06         | _  |
| No   | 36 (69.2%)               | 16 (30.8%)               |             |  |
| lopidogrel responders <sup>b</sup>         |                          |                          |             |  |
| Yes  | 54 (85.7%)               | 9 (14.3%)                | .2          | _  |
| No   | 10 (71.4%)               | 4 (28.6%)                |             |  |
| djunctive coiling                          |                          |                          |             |  |
| Yes  | 33 (82.5%)               | 7 (17.5%)                | .36         | -  |
| No   | 67 (75.3%)               | 22 (24.7%)               |             | 00 11 05-1                               |
| No. of Pipelines deployed (median) (range) | 1 (1–14)                 | 2 (1–9)                  | .03         | OR, 1.1; 95% CI, 0.9–1.4; P = .4         |
| ength of procedure (median) (range) (min)  | 104 (22–360)             | 145 (42–410)             | .04         | OR, 1; 95% CI, 0.9–1.01; $P = .1$        |
| ranch status                               | 77 /72 00/               | 27 /2 ( 20/)             | 0.4         | OD 27,059/ CL 25, 12, 4, 5               |
| Covered                                    | 76 (73.8%)               | 27 (26.2%)               | .04         | OR, 2.6; 95% CI, 0.5–12.4; $P = .24$     |
| Not covered                                | 24 (92.3%)               | 2 (7.7%)                 |             |  |
| No. of covered branches                    | A7 /71 20/\              | 10 (20 00/)              | 42          |  |
| ≤2<br>>2                                   | 47 (71.2%)<br>20 (78.4%  | 19 (28.8%)<br>8 (21.6%)  | .43         | _  |
|  | 29 (78.4%                | 8 (21.6%)                |             |  |
| overed branches status                     |                          |                          |             |  |
| Covered branches status Occluded           | 18 (85.7%)               | 3 (14.3%)                | .16         | _  |

**Note:**—SCA indicates superior cerebellar artery.

<sup>a</sup> Data are missing in 9 procedures.

<sup>b</sup> Among patients with platelet function testing.